Acute Kidney Injury as a Risk Factor for Myocardial Injury and Ventricular Dysfunction

Acute Kidney Injury Clinical Trial

Official title:

Assessment of Acute Kidney Injury as a Risk Factor for Myocardial Injury and Ventricular Systolic Dysfunction After Non-Cardiac Surgery in Critical Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04768751
• Other study ID #: Acute Kidney injury
• Status: Completed
• Start date: March 5, 2019
• Est. completion date: August 30, 2020

Study information

• Verified date: February 2021
• Source: South Egypt Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute kidney injury (AKI) is classically described as an abrupt or rapidly reversible reduction in the excretion of nitrogenous waste products, including urea, nitrogen and creatinine. Acute kidney injury definition emphasizes on the filtration function of the kidney, a measure that is unique and easily and routinely measured .

Acute kidney injury is associated with significantly increased resource utilization and health care costs.

Major adverse cardiac events (MACE) after non cardiac surgery are a leading cause of morbidity and mortality. The reported incidence of postoperative myocardial infarction (POMI) among patients undergoing non cardiac surgery is between 3% and 6%.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 520
• Est. completion date: August 30, 2020
• Est. primary completion date: August 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with normal kidney functions and free normal heart functions, were enrolled to this study

Exclusion Criteria:

• patients with chronic kidney disease, cardiac disease, who with minor operations, or emergency, were excluded from the study.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Myocardium; Injury
• Ventricular Dysfunction
• Wounds and Injuries

Intervention

Diagnostic Test:
• kidney assessment
Urea, BUN, and Creatinine BLOOD LEVELS

Locations

Country	Name	City	State
Egypt	Alaa Ali Elzohry	Assuit

Sponsors (1)

Lead Sponsor	Collaborator
South Egypt Cancer Institute

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	development myocardial injury	New echocardiographic findings suggestive of ischemia (new regional wall motion abnormalities) or cardiac troponin T >.0.32 ng/ml	through study completion, an average of 15 days